Core Insights - Telomir Pharmaceuticals, Inc. has been added to the Russell 3000® and Russell Microcap® Indexes, effective July 1, 2024, indicating significant progress as a publicly-traded company since its IPO in February 2024 [1][6][11] Company Overview - Telomir Pharmaceuticals is a pre-clinical-stage pharmaceutical company focused on developing and commercializing Telomir-1, a novel small molecule aimed at lengthening DNA's protective telomere caps to potentially treat age-related conditions [1][13] - The company aims to address a range of age-related inflammatory conditions, including osteoarthritis, through the oral administration of Telomir-1 [13] Industry Context - The Russell indexes are widely utilized by investment managers and institutional investors, with approximately $10.5 trillion in assets benchmarked against these indexes as of December 2023 [2][11] - Membership in the Russell 3000® and Russell Microcap® Indexes provides automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, enhancing visibility and credibility in the market [11]
Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes